Long-term use of vitamin K antagonists and incidence of cancer: A population-based study

Blood

Volumn 117, Issue 5, 2011, Pages 1707-1709

  Pengo, Vittorio ^a   Noventa, Franco ^b   Denas, Gentian ^a   Pengo, Martino F ^b   Gallo, Umberto ^c   Grion, Anna Maria ^c   Iliceto, Sabino ^a   Prandoni, Paolo ^b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Pharmaceutical Service   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; WARFARIN;

AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; SEX;

EID: 79551642187     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-304758     Document Type: Article

References (20)

1. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 2001;53(1):93-105. (Pubitemid 32173109)
2. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315(26):1650-1659.
3. Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Semin Thromb Hemost. 1998;24(2):93-109.
4. Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost. 2003;1(7):1456-1463.
5. Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost. 2006;32(1):5-10.
6. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med. 2000;342(26):1953-1958.
7. Tagalakis V, Tamim H, Blostein M, et al. Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol. 2007;8(5):395-402. (Pubitemid 46621759)
8. Baron JA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer. Lancet. 1998;351(9109):1077-1080.
9. Sørensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338(17):1169-1173. (Pubitemid 28180744)
10. Koopman PAR. Confidence limits for the ratio of two binomial proportions. Biometrics. 1984;40(2):513-517.
11. Wu YM, Robinson DR, Kung HJ. Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res. 2004;64(20):7311-7320.
12. Sainaghi PP, Costello L, Bergamasco L, et al. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol. 2005;204(1):36-44. (Pubitemid 40776804)
13. Hasanbasic I, Rajotte I, Blostein M. The role of g-carboxylation in the anti-apoptotic effect of gas6 in endothelium. J Thromb Haemost. 2005;3(12):2790-2797. (Pubitemid 41819809)
14. Shiozawa Y, Pedersen EA, Patel LR, et al. GAS6/ AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia. 2010;12(2):116-127.
15. Omarbasha B, Fair WR, Heston WD. Effect of coumarin on normal rat prostate and R-3327H prostatic adenocarcinoma. Cancer Res. 1989;49(11):3045- 3049. (Pubitemid 19148646)
16. Carpi A, Sagripanti A, Poddighe R, et al. Cancer incidence and mortality in patients with heart disease: effect of oral anticoagulant therapy. Am J Clin Oncol. 1995;18(1):15-18.
17. Michaels L. Cancer incidence and mortality in patients having anticoagulant therapy. Lancet. 1964;2(7364):832-835.
18. Annegers JF, Zacharski LR. Cancer morbidity and mortality in previously anticoagulated patients. Thromb Res. 1980;18(3-4):399-403.
19. Blumentals WA, Foulis PR, Schwartz SW, et al. Does warfarin therapy influence the risk of bladder cancer? Thromb Haemost. 2004;91(4):801-805.
20. Taliani MR, Agnelli G, Prandoni P, et al. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost. 2003;1(8):1730-1733.